Prevalence and Clinicopathologic Risk Factors for Epidermal Growth Factor Receptor, Anaplastic Lymphoma Kinase, and ROS-1 Fusion in Metastatic Non-small Cell Lung Carcinoma

The purpose of he study was to evaluate the prevalence of epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK), and ROS-1 fusions in the patients with metastatic nonsquamous nonsmall cell lung carcinoma (NSCLC) and their relation with different demographic and clinical variables. Methods: A cross-sectional study was carried out on 87 adult patients >18 years of age with a confirmed diagnosis of Stage IV metastatic NSCLC. All the patients were studied for EGFR mutations, ALK, and ROS-1 fusions. The outcome measures were the presence of EGFR, ALK, and ROS-1 fusions among the patients with NSCLC and the risk association with age, gender, smoking, and tumor differentiation. Results: Out of 87 patients, 26 (29.89%) patients tested positive for EGFR mutations, 4 (4.6%) for ALK, and a single case for ROS-1 fusion. The mean age of the patients who were EGFR positive was significantly younger than the mean age of those without EGFR mutation (56.77 ± 12.01 vs. 66.6..... READ ARTICLE

Journal of Radiation and Cancer Research DOI:10.4103/jrcr.jrcr_43_21

Authors: Raghav Kesri, Hari Goyal, Geetanjali Gupta, Deepak Bharti and Richu Sharma